1-anilino-8-naphthalenesulfonate has been researched along with Peripheral Nerve Diseases in 2 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eligible patients had solid tumors for which treatment with carboplatin/paclitaxel was appropriate." | 2.71 | A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. ( Arezzo, J; Bartley, P; Chia, M; Daly, M; Davis, ID; Green, M; Harrison, L; Kiers, L; MacGregor, L; Michael, M; Quinn, M; Rosenthal, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wen, PY | 1 |
| Davis, ID | 1 |
| Kiers, L | 1 |
| MacGregor, L | 1 |
| Quinn, M | 1 |
| Arezzo, J | 1 |
| Green, M | 1 |
| Rosenthal, M | 1 |
| Chia, M | 1 |
| Michael, M | 1 |
| Bartley, P | 1 |
| Harrison, L | 1 |
| Daly, M | 1 |
1 trial available for 1-anilino-8-naphthalenesulfonate and Peripheral Nerve Diseases
| Article | Year |
|---|---|
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytokines; Dose-Response R | 2005 |
1 other study available for 1-anilino-8-naphthalenesulfonate and Peripheral Nerve Diseases
| Article | Year |
|---|---|
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Cytokines; Double-Blind Method; Humans; Interleukin-6; Leukemia Inhibitory Fa | 2005 |